ELANCO ANIMAL HEALTH INC (5EA.DE) Fundamental Analysis & Valuation

FRA:5EA • US28414H1032

Current stock price

19.75 EUR
-0.3 (-1.52%)
Last:

This 5EA.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. 5EA.DE Profitability Analysis

1.1 Basic Checks

  • In the past year 5EA was profitable.
  • 5EA had a positive operating cash flow in the past year.
  • 5EA had negative earnings in 4 of the past 5 years.
  • In the past 5 years 5EA always reported a positive cash flow from operatings.
5EA.DE Yearly Net Income VS EBIT VS OCF VS FCF5EA.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B

1.2 Ratios

  • 5EA has a worse Return On Assets (-1.74%) than 63.46% of its industry peers.
  • 5EA has a worse Return On Equity (-3.54%) than 63.46% of its industry peers.
  • 5EA has a worse Return On Invested Capital (1.48%) than 63.46% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for 5EA is significantly below the industry average of 17.75%.
Industry RankSector Rank
ROA -1.74%
ROE -3.54%
ROIC 1.48%
ROA(3y)-2.54%
ROA(5y)-2.21%
ROE(3y)-5.93%
ROE(5y)-5.05%
ROIC(3y)1.58%
ROIC(5y)1.62%
5EA.DE Yearly ROA, ROE, ROIC5EA.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 -10 -15

1.3 Margins

  • 5EA has a Operating Margin (5.34%) which is in line with its industry peers.
  • In the last couple of years the Operating Margin of 5EA has declined.
  • 5EA has a worse Gross Margin (54.99%) than 71.15% of its industry peers.
  • 5EA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 5.34%
PM (TTM) N/A
GM 54.99%
OM growth 3Y-15.01%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.97%
GM growth 5Y2.32%
5EA.DE Yearly Profit, Operating, Gross Margins5EA.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. 5EA.DE Health Analysis

2.1 Basic Checks

  • 5EA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, 5EA has more shares outstanding
  • Compared to 5 years ago, 5EA has more shares outstanding
  • 5EA has a better debt/assets ratio than last year.
5EA.DE Yearly Shares Outstanding5EA.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
5EA.DE Yearly Total Debt VS Total Assets5EA.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • Based on the Altman-Z score of 1.35, we must say that 5EA is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.35, 5EA is doing worse than 65.38% of the companies in the same industry.
  • 5EA has a debt to FCF ratio of 14.14. This is a negative value and a sign of low solvency as 5EA would need 14.14 years to pay back of all of its debts.
  • 5EA has a worse Debt to FCF ratio (14.14) than 67.31% of its industry peers.
  • 5EA has a Debt/Equity ratio of 0.60. This is a neutral value indicating 5EA is somewhat dependend on debt financing.
  • The Debt to Equity ratio of 5EA (0.60) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF 14.14
Altman-Z 1.35
ROIC/WACC0.17
WACC8.78%
5EA.DE Yearly LT Debt VS Equity VS FCF5EA.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B

2.3 Liquidity

  • 5EA has a Current Ratio of 2.17. This indicates that 5EA is financially healthy and has no problem in meeting its short term obligations.
  • 5EA's Current ratio of 2.17 is fine compared to the rest of the industry. 5EA outperforms 71.15% of its industry peers.
  • A Quick Ratio of 1.08 indicates that 5EA should not have too much problems paying its short term obligations.
  • 5EA has a Quick ratio (1.08) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.17
Quick Ratio 1.08
5EA.DE Yearly Current Assets VS Current Liabilites5EA.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. 5EA.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 4.40% over the past year.
  • The Earnings Per Share has been growing by 15.11% on average over the past years. This is quite good.
  • Looking at the last year, 5EA shows a small growth in Revenue. The Revenue has grown by 6.22% in the last year.
  • 5EA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.59% yearly.
EPS 1Y (TTM)4.4%
EPS 3Y-5.06%
EPS 5Y15.11%
EPS Q2Q%-7.14%
Revenue 1Y (TTM)6.22%
Revenue growth 3Y2.25%
Revenue growth 5Y7.59%
Sales Q2Q%12.16%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.15% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 4.86% on average over the next years.
EPS Next Y10.73%
EPS Next 2Y11.57%
EPS Next 3Y12.11%
EPS Next 5Y10.15%
Revenue Next Year7.56%
Revenue Next 2Y6.22%
Revenue Next 3Y5.76%
Revenue Next 5Y4.86%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
5EA.DE Yearly Revenue VS Estimates5EA.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
5EA.DE Yearly EPS VS Estimates5EA.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

2

4. 5EA.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 24.09 indicates a rather expensive valuation of 5EA.
  • The rest of the industry has a similar Price/Earnings ratio as 5EA.
  • 5EA is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 24.75, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 21.69, which indicates a rather expensive current valuation of 5EA.
  • 5EA's Price/Forward Earnings is on the same level as the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 22.10. 5EA is around the same levels.
Industry RankSector Rank
PE 24.09
Fwd PE 21.69
5EA.DE Price Earnings VS Forward Price Earnings5EA.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20

4.2 Price Multiples

  • 5EA's Enterprise Value to EBITDA ratio is in line with the industry average.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of 5EA indicates a slightly more expensive valuation: 5EA is more expensive than 63.46% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 39.95
EV/EBITDA 15.9
5EA.DE Per share data5EA.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 5EA does not grow enough to justify the current Price/Earnings ratio.
  • 5EA's earnings are expected to grow with 12.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.24
PEG (5Y)1.59
EPS Next 2Y11.57%
EPS Next 3Y12.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 5EA.DE Dividend Analysis

5.1 Amount

  • No dividends for 5EA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

5EA.DE Fundamentals: All Metrics, Ratios and Statistics

ELANCO ANIMAL HEALTH INC

FRA:5EA (3/13/2026, 7:00:00 PM)

19.75

-0.3 (-1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-05
Inst Owners109.64%
Inst Owner ChangeN/A
Ins Owners0.98%
Ins Owner ChangeN/A
Market Cap9.82B
Revenue(TTM)4.71B
Net Income(TTM)-232.00M
Analysts85.45
Price Target22.49 (13.87%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.98%
Min EPS beat(2)15.04%
Max EPS beat(2)42.93%
EPS beat(4)4
Avg EPS beat(4)26.36%
Min EPS beat(4)15.04%
Max EPS beat(4)42.93%
EPS beat(8)7
Avg EPS beat(8)19.17%
EPS beat(12)10
Avg EPS beat(12)41.51%
EPS beat(16)13
Avg EPS beat(16)37.85%
Revenue beat(2)2
Avg Revenue beat(2)2.33%
Min Revenue beat(2)2.06%
Max Revenue beat(2)2.6%
Revenue beat(4)4
Avg Revenue beat(4)1.81%
Min Revenue beat(4)0.08%
Max Revenue beat(4)2.6%
Revenue beat(8)6
Avg Revenue beat(8)0.67%
Revenue beat(12)10
Avg Revenue beat(12)1%
Revenue beat(16)10
Avg Revenue beat(16)0.22%
PT rev (1m)0%
PT rev (3m)1.9%
EPS NQ rev (1m)-1.36%
EPS NQ rev (3m)-1.36%
EPS NY rev (1m)0.62%
EPS NY rev (3m)-0.24%
Revenue NQ rev (1m)0.69%
Revenue NQ rev (3m)0.61%
Revenue NY rev (1m)1.67%
Revenue NY rev (3m)1.73%
Valuation
Industry RankSector Rank
PE 24.09
Fwd PE 21.69
P/S 2.41
P/FCF 39.95
P/OCF 20.26
P/B 1.73
P/tB N/A
EV/EBITDA 15.9
EPS(TTM)0.82
EY4.15%
EPS(NY)0.91
Fwd EY4.61%
FCF(TTM)0.49
FCFY2.5%
OCF(TTM)0.97
OCFY4.94%
SpS8.21
BVpS11.4
TBVpS-2.85
PEG (NY)2.24
PEG (5Y)1.59
Graham Number14.5
Profitability
Industry RankSector Rank
ROA -1.74%
ROE -3.54%
ROCE 2.14%
ROIC 1.48%
ROICexc 1.56%
ROICexgc 5.76%
OM 5.34%
PM (TTM) N/A
GM 54.99%
FCFM 6.02%
ROA(3y)-2.54%
ROA(5y)-2.21%
ROE(3y)-5.93%
ROE(5y)-5.05%
ROIC(3y)1.58%
ROIC(5y)1.62%
ROICexc(3y)1.64%
ROICexc(5y)1.68%
ROICexgc(3y)6.4%
ROICexgc(5y)7.61%
ROCE(3y)2.28%
ROCE(5y)2.34%
ROICexgc growth 3Y-17.32%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.69%
ROICexc growth 5YN/A
OM growth 3Y-15.01%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.97%
GM growth 5Y2.32%
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF 14.14
Debt/EBITDA 4.23
Cap/Depr 40.59%
Cap/Sales 5.85%
Interest Coverage 250
Cash Conversion 60.09%
Profit Quality N/A
Current Ratio 2.17
Quick Ratio 1.08
Altman-Z 1.35
F-Score5
WACC8.78%
ROIC/WACC0.17
Cap/Depr(3y)29.03%
Cap/Depr(5y)28.32%
Cap/Sales(3y)4.32%
Cap/Sales(5y)4.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.4%
EPS 3Y-5.06%
EPS 5Y15.11%
EPS Q2Q%-7.14%
EPS Next Y10.73%
EPS Next 2Y11.57%
EPS Next 3Y12.11%
EPS Next 5Y10.15%
Revenue 1Y (TTM)6.22%
Revenue growth 3Y2.25%
Revenue growth 5Y7.59%
Sales Q2Q%12.16%
Revenue Next Year7.56%
Revenue Next 2Y6.22%
Revenue Next 3Y5.76%
Revenue Next 5Y4.86%
EBIT growth 1Y0.4%
EBIT growth 3Y-13.1%
EBIT growth 5YN/A
EBIT Next Year40.58%
EBIT Next 3Y18.81%
EBIT Next 5Y13.31%
FCF growth 1Y-25.26%
FCF growth 3Y1.95%
FCF growth 5YN/A
OCF growth 1Y3.51%
OCF growth 3Y7.4%
OCF growth 5YN/A

ELANCO ANIMAL HEALTH INC / 5EA.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ELANCO ANIMAL HEALTH INC?

ChartMill assigns a fundamental rating of 3 / 10 to 5EA.DE.


What is the valuation status for 5EA stock?

ChartMill assigns a valuation rating of 2 / 10 to ELANCO ANIMAL HEALTH INC (5EA.DE). This can be considered as Overvalued.


How profitable is ELANCO ANIMAL HEALTH INC (5EA.DE) stock?

ELANCO ANIMAL HEALTH INC (5EA.DE) has a profitability rating of 2 / 10.


How financially healthy is ELANCO ANIMAL HEALTH INC?

The financial health rating of ELANCO ANIMAL HEALTH INC (5EA.DE) is 3 / 10.